comparemela.com
Home
Live Updates
Novavax, Inc.: Results from Novavax NanoFlu Influenza Vaccin
Novavax, Inc.: Results from Novavax NanoFlu Influenza Vaccin
Novavax, Inc.: Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu vaccine candidate induced significantly
Related Keywords
Laura Keenan Lindsey ,
Erika Schultz ,
Stanleyc Erck ,
Alexandra Roy ,
Ali Chartan ,
Exchange Commission ,
Linkedin ,
Twitter ,
Prnewswire Novavax Inc ,
Nasdaq ,
Novavax Inc ,
Lancet Infectious Diseases ,
Chief Executive Officer ,
Financial Condition ,
Novavax Annual Report ,
Quarterly Reports ,
Keenan Lindsey ,
எரிகா ஶுல்ட்ஸ் ,
அலெக்சாண்ட்ரா ராய் ,
பரிமாற்றம் தரகு ,
சென்டர் ,
ட்விட்டர் ,
நாஸ்டாக் ,
தலைமை நிர்வாகி அதிகாரி ,
நிதி நிலை ,
காலாண்டு அறிக்கைகள் ,
Novavax ,
Results ,
Rom ,
Nanoflu ,
Influenza ,
Vaccine ,
Hase ,
Linical ,
Trial ,
Published ,
Lancet ,
Nfectious ,
Diseases ,